Product category:
Detectors, sensors and probes
News Release from: Biacore | Subject: BiacoreS51
Edited by the Laboratorytalk Editorial
Team on 30 September 2003
Characterisation of drug-kinase
interactions
Biacore held a technical tutorial at the Society of Biomolecular Screening meeting to demonstrate the value of its drug discovery platform in protein kinase studies
Biacore held a technical tutorial, including a presentation and a poster session, at the Society of Biomolecular Screening meeting The presentation demonstrated the value of Biacore's drug discovery platform, BiacoreS51, in protein kinase studies
This article was originally published on Laboratorytalk on 6 Dec 2002 at 8.00am (UK)
Related stories
Making the most of biomolecular studies
New interactive technical support tools on CD give researchers easy access to published information on surface plasmon resonance technology
New technology for proteomics research
High performance SPR-based research system for studying biomolecular interactions has been made more powerful through the incorporation of increased capacity recovery
Protein kinases represent an extremely important class of therapeutic targets for a wide range of human diseases.
The complexity and diversity of kinase pathways, however, place high demands on the techniques needed to provide high quality information for drug development in this area.
Data included in the presentation illustrated the use of Biacore's SPR technology in a range of different kinase applications.
BiacoreS51 was used, for example, to screen and evaluate kinase inhibitor lead compounds, identify inhibitor-binding sites on kinases and to compare inhibitor and substrate specificities for active/inactive kinases.
Julian Abery, vice president and gead of the pharmaceutical and biotechnology business unit at Biacore, commented, "The label-free, real time analysis provided by our SPR technology offers significant advantages over other techniques.
"Data obtained by SPR in these studies were highly consistent with those obtained using radiometric assays, but without the inconveniences of radioactive labeling.
"The ability to directly monitor compound binding to kinase or substrate, evaluate specificity and selectivity and determine kinetics, all from one instrument, makes BiacoreS51 ideal for the detailed characterisation of potential therapeutics directed against kinases.".
• Biacore: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
